Evidence map›Paper›PMID 35420316›Full record

ArticleBreast cancer research and treatment2022

Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer.

Temidayo A Fadelu, Parsa Erfani, Joarly Lormil, Ruth Damuse, Viergela Pierre, Sarah Slater, Scott A Triedman, Lawrence N Shulman, Timothy R Rebbeck

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Temidayo A FadeluDana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA. temidayo_fadelu@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-1323-4119
Parsa ErfaniHarvard Medical School, Boston, MA, USA.
Joarly LormilHôpital Universitaire de Mirebalais, Mirebalais, Haiti.
Ruth DamuseHôpital Universitaire de Mirebalais, Mirebalais, Haiti.
Viergela PierreHôpital Universitaire de Mirebalais, Mirebalais, Haiti.
Sarah SlaterDana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA.
Scott A TriedmanDana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA.
Lawrence N ShulmanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Timothy R RebbeckDana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA.

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Conquer Cancer Foundation 2019 Young Investigator Award in Breast CancerDana-Farber Cancer Institute Early Career Faculty Innovation GrantFIC NIH HHS D43 TW010543FIC NIH HHS Trainee under Award Number D43 TW010543
6 · The paper itself

Abstract

backgroundThere are limited data on breast surgery completion rates and prevalence of care-continuum delays in breast cancer treatment programs in low-income countries.

methodsThis study analyzes treatment data in a retrospective cohort of 312 female patients with non-metastatic breast cancer in Haiti. Descriptive statistics were used to summarize patient characteristics; treatments received; and treatment delays of > 12 weeks. Multivariate logistic regressions were performed to identify factors associated with receiving surgery and with treatment delays. Exploratory multivariate survival analysis examined the association between surgery delays and disease-free survival (DFS).

resultsOf 312 patients, 249 (80%) completed breast surgery. The odds ratio (OR) for surgery completion for urban vs. rural dwellers was 2.15 (95% confidence interval [CI]: 1.19-3.88) and for those with locally advanced vs. early-stage disease was 0.34 (95%CI: 0.16-0.73). Among the 223 patients with evaluable surgery completion timelines, 96 (43%) experienced delays. Of the 221 patients eligible for adjuvant chemotherapy, 141 (64%) received adjuvant chemotherapy, 66 of whom (47%) experienced delays in chemotherapy initiation. Presentation in the later years of the cohort (2015-2016) was associated with lower rates of surgery completion (75% vs. 85%) and with delays in adjuvant chemotherapy initiation (OR [95%CI]: 3.25 [1.50-7.06]). Exploratory analysis revealed no association between surgical delays and DFS.

conclusionWhile majority of patients obtained curative-intent surgery, nearly half experienced delays in surgery and adjuvant chemotherapy initiation. Although our study was not powered to identify an association between surgical delays and DFS, these delays may negatively impact long-term outcomes.

Indexed as

Breast NeoplasmsChemotherapy, AdjuvantFemaleHaitiHumansMastectomyRetrospective StudiesBreast cancerBreast surgeryCare delaysGlobal healthGlobal surgeryHealth disparitiesLow- and middle-income countries (LMICs)

Identifiers

PMID35420316
PMCPMC9114044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.